Icon and Medpace report high R&D project cancellations; Icon sees $659M in Q1 cancellations, cuts guidance; Medpace notes ...

Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

When Siren Biotechnology CEO Nicole Paulk learned last month that top FDA official Peter Marks had resigned, she began ...

Arvinas, along with its partner Pfizer, cancelled plans for a Phase 3 trial combining its PROTAC vepdegestrant with its CDK4 ...

Eli Lilly posted $12.73 billion in revenue in the first quarter, a 45% jump from the prior year, matching the percentage ...

Stately Bio has raised a $12 million seed round led by AIX Ventures to advance machine learning techniques that recognize ...

Regeneron can’t dodge a lawsuit alleging it unlawfully inflated Medicare reimbursements for its eye drug Eylea and defrauded ...

Teladoc has bought virtual therapy startup UpLift to sell mental health treatment, including treatment from its ...

Artios Pharma, a startup developing drugs that weaken a tumor’s ability to maintain its DNA, announced positive results in a ...

A tribunal within the US Patent and Trademark Office invalidated several claims of a patent held by AbbVie’s Pharmacyclics, ...

Top cancer scientists, former NIH leaders, and patient advocates warned that the Trump administration's cuts to science ...

Noma Therapy, a virtual ketamine-assisted therapy provider, has launched with $4.25 million in funding, Endpoints News ...